Literature DB >> 23968589

Opioid self-administration results in cell-type specific adaptations of striatal medium spiny neurons.

Alex S James1, Jane Y Chen, Carlos Cepeda, Nitish Mittal, James David Jentsch, Michael S Levine, Christopher J Evans, Wendy Walwyn.   

Abstract

Medium-sized spiny neurons (MSNs), the predominant neuronal population of the striatum, are an integral component of the many cortical and limbic pathways associated with reward-related behaviors. A differential role of the D1 receptor-enriched (D1) MSNs of the striatonigral direct pathway, as compared with the D2 receptor-enriched (D2) MSNs of the striatopallidal indirect pathway, in mediating the addictive behaviors associated with cocaine is beginning to emerge. However, whether opioids, well-known analgesics with euphoric properties, similarly induce dissociable signaling adaptations in these neurons remains unclear. Transgenic mice expressing green fluorescent protein (GFP)-labeled D1 or D2 neurons were implanted with intravenous jugular catheters. Mice learned to self-administer 0.1mg/kg/infusion of the opioid remifentanil during 2h sessions over 13 contiguous days. Thereafter, the electrophysiological properties of D1- and D2-MSNs in the shell region of the nucleus accumbens (NAc) were assessed. We found that prior opioid exposure did not alter the basic membrane properties nor the kinetics or amplitude of miniature excitatory postsynaptic currents (mEPSCs). However, when challenged with the mu opioid receptor (μOR) agonist DAMGO, the characteristic inhibitory profile of this receptor was altered. DAMGO inhibited the frequency of mEPSCs in D1-MSNs from control mice receiving saline and in D2-MSNs from mice exposed to remifentanil or saline, but this inhibitory profile was reduced in D1-MSNs from mice receiving remifentanil. Remifentanil exposure also altered the probability of glutamate release onto D1-, but not D2-MSNs. Together these results suggest a D1-pathway specific effect associated with the acquisition of opioid-seeking behaviors.
Copyright © 2013 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Electrophysiology; Intravenous self-administration; Medium spiny neurons; Mice; Mu opioid receptor; Striatum

Mesh:

Substances:

Year:  2013        PMID: 23968589      PMCID: PMC3815993          DOI: 10.1016/j.bbr.2013.08.009

Source DB:  PubMed          Journal:  Behav Brain Res        ISSN: 0166-4328            Impact factor:   3.332


  24 in total

1.  Distinct roles of synaptic transmission in direct and indirect striatal pathways to reward and aversive behavior.

Authors:  Takatoshi Hikida; Kensuke Kimura; Norio Wada; Kazuo Funabiki; Shigetada Nakanishi
Journal:  Neuron       Date:  2010-06-24       Impact factor: 17.173

2.  Nucleus accumbens D2- and D1-receptor expressing medium spiny neurons are selectively activated by morphine withdrawal and acute morphine, respectively.

Authors:  T Enoksson; J Bertran-Gonzalez; M J Christie
Journal:  Neuropharmacology       Date:  2012-03-03       Impact factor: 5.250

3.  Functional mu opioid receptors are expressed in cholinergic interneurons of the rat dorsal striatum: territorial specificity and diurnal variation.

Authors:  Maritza Jabourian; Laurent Venance; Sylvie Bourgoin; Sylvie Ozon; Sylvie Pérez; Gérard Godeheu; Jacques Glowinski; Marie-Louise Kemel
Journal:  Eur J Neurosci       Date:  2005-06       Impact factor: 3.386

4.  Cooperative activation of dopamine D1 and D2 receptors increases spike firing of nucleus accumbens neurons via G-protein betagamma subunits.

Authors:  F Woodward Hopf; Maria Grazia Cascini; Adrienne S Gordon; Ivan Diamond; Antonello Bonci
Journal:  J Neurosci       Date:  2003-06-15       Impact factor: 6.167

5.  Cocaine self-administration behavior in inbred mouse lines segregating different capacities for inhibitory control.

Authors:  M Catalina Cervantes; Rick E Laughlin; J David Jentsch
Journal:  Psychopharmacology (Berl)       Date:  2013-05-17       Impact factor: 4.530

Review 6.  Regulation of drug-taking and -seeking behaviors by neuroadaptations in the mesolimbic dopamine system.

Authors:  David W Self
Journal:  Neuropharmacology       Date:  2004       Impact factor: 5.250

7.  Differential innervation of direct- and indirect-pathway striatal projection neurons.

Authors:  Nicholas R Wall; Mauricio De La Parra; Edward M Callaway; Anatol C Kreitzer
Journal:  Neuron       Date:  2013-06-27       Impact factor: 17.173

8.  Dopaminergic and cholinergic influences on morphine self-administration in rats.

Authors:  S D Glick; R D Cox
Journal:  Res Commun Chem Pathol Pharmacol       Date:  1975-09

9.  A gene expression atlas of the central nervous system based on bacterial artificial chromosomes.

Authors:  Shiaoching Gong; Chen Zheng; Martin L Doughty; Kasia Losos; Nicholas Didkovsky; Uta B Schambra; Norma J Nowak; Alexandra Joyner; Gabrielle Leblanc; Mary E Hatten; Nathaniel Heintz
Journal:  Nature       Date:  2003-10-30       Impact factor: 49.962

10.  Regional and cell-type-specific effects of DAMGO on striatal D1 and D2 dopamine receptor-expressing medium-sized spiny neurons.

Authors:  Yao-Ying Ma; Carlos Cepeda; Payush Chatta; Lana Franklin; Christopher J Evans; Michael S Levine
Journal:  ASN Neuro       Date:  2012-03-08       Impact factor: 4.146

View more
  14 in total

1.  Reversal of morphine-induced cell-type-specific synaptic plasticity in the nucleus accumbens shell blocks reinstatement.

Authors:  Matthew C Hearing; Jakub Jedynak; Stephanie R Ebner; Anna Ingebretson; Anders J Asp; Rachel A Fischer; Clare Schmidt; Erin B Larson; Mark John Thomas
Journal:  Proc Natl Acad Sci U S A       Date:  2016-01-06       Impact factor: 11.205

Review 2.  Prefrontal-accumbens opioid plasticity: Implications for relapse and dependence.

Authors:  Matthew Hearing
Journal:  Pharmacol Res       Date:  2018-11-19       Impact factor: 7.658

3.  Chemogenetic inhibition of corticostriatal circuits reduces cued reinstatement of methamphetamine seeking.

Authors:  Angela M Kearns; Benjamin M Siemsen; Jordan L Hopkins; Rachel A Weber; Michael D Scofield; Jamie Peters; Carmela M Reichel
Journal:  Addict Biol       Date:  2021-08-25       Impact factor: 4.280

Review 4.  A novel approach to treating opioid use disorders: Dual agonists of glucagon-like peptide-1 receptors and neuropeptide Y2 receptors.

Authors:  Riley Merkel; Amanda Moreno; Yafang Zhang; Rachel Herman; Jennifer Ben Nathan; Sana Zeb; Suditi Rahematpura; Kamryn Stecyk; Brandon T Milliken; Matthew R Hayes; Robert P Doyle; Heath D Schmidt
Journal:  Neurosci Biobehav Rev       Date:  2021-10-29       Impact factor: 8.989

Review 5.  Opioid Receptor-Mediated Regulation of Neurotransmission in the Brain.

Authors:  Kaitlin C Reeves; Nikhil Shah; Braulio Muñoz; Brady K Atwood
Journal:  Front Mol Neurosci       Date:  2022-06-15       Impact factor: 6.261

Review 6.  The Opioid-Addicted Tetrapartite Synapse.

Authors:  Anna Kruyer; Vivian C Chioma; Peter W Kalivas
Journal:  Biol Psychiatry       Date:  2019-06-13       Impact factor: 13.382

7.  Activation of GLP-1 receptors attenuates oxycodone taking and seeking without compromising the antinociceptive effects of oxycodone in rats.

Authors:  Yafang Zhang; Michelle W Kahng; Jaclynn A Elkind; Vanessa R Weir; Nicole S Hernandez; Lauren M Stein; Heath D Schmidt
Journal:  Neuropsychopharmacology       Date:  2019-10-03       Impact factor: 7.853

Review 8.  Persistent effects of obesity: a neuroplasticity hypothesis.

Authors:  Bridget A Matikainen-Ankney; Alexxai V Kravitz
Journal:  Ann N Y Acad Sci       Date:  2018-05-09       Impact factor: 5.691

Review 9.  Glutamatergic Systems and Memory Mechanisms Underlying Opioid Addiction.

Authors:  Jasper A Heinsbroek; Taco J De Vries; Jamie Peters
Journal:  Cold Spring Harb Perspect Med       Date:  2021-03-01       Impact factor: 6.915

10.  Remifentanil self-administration in mice promotes sex-specific prefrontal cortex dysfunction underlying deficits in cognitive flexibility.

Authors:  Eden M Anderson; Annabel Engelhardt; Skyler Demis; Elissa Porath; Matthew C Hearing
Journal:  Neuropsychopharmacology       Date:  2021-05-19       Impact factor: 8.294

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.